American Kidney Fund

We are in a new era of kidney care – but more needs to be done to realize its potential. That’s why we’re excited to announce a new report, “Healthy Workforces, Sustainable Futures: Why Employers Should Invest in Early Kidney Care,” in partnership with the National Alliance of Healthcare Purchaser Coalitions. The report examines the impact of CKD on the US workforce and identifies solutions that employers can implement to keep employees healthier, more productive, all while reducing health care costs. With over 11 million workers impacted by CKD, we need to act now to ensure they have access to the care and treatment they need to stop the progression of their disease. Working together, we can change the trajectory of CKD in the US. Read more: https://bit.ly/4c5pXb3 #KidneyHealth #WorkplaceWellnes

Olympic gold medalist Suni Lee recently opened up to Women’s Health, sharing her journey of being diagnosed with two rare kidney diseases and the incredible physical and mental challenges she overcame on her way to winning three medals at the 2024 Paris Olympics. 🏅✨ “One of the most overwhelming feelings when I was diagnosed with kidney disease was loneliness. I felt like no one understood what I was going through, and the doctors weren’t listening to me. But since sharing my kidney disease journey, I've received an overwhelming number of supportive and heartfelt messages from an entire community of people living with kidney disease. I realized that I'm not alone.” - Suni Lee Read Suni’s full blog via Women’s Health: https://bit.ly/4kW6EVL

We are excited to announce the 2025 AKF Clinical Scientist in Nephrology (CSN) fellows! Join us in congratulating Dr. Momen Abbasi, a nephrology fellow at the University of Illinois College of Medicine and Dr. Api Chewcharat, a nephrology fellow at Mass General Brigham Research. Dr. Abbasi is working on developing and testing non-invasive ways to assess kidney damage using advanced imaging techniques so that patients who are at a higher risk of worsening kidney function can be identified. Dr. Chewcharat is studying whether biomarkers can be used to detect thrombotic microangiopathy (TA-TMA), a serious complication that can occur after a stem cell transplant and may severely damage the kidneys, as well as the possibility of creating a predictive tool to assess which patients with TA-TMA are at high risk of requiring dialysis and/or death.  Dr. Abbasi and Dr. Chewcharat join a distinguished roster of more than 50 top nephrology researchers who received early-career support from AKF through the Clinical Scientist in Nephrology Program. Their fellowships are funded by a generous grant from Akebia Therapeutics and an anonymous donor. Learn more: https://lnkd.in/endVBUtA

We're hiring! AKF is looking for an Associate Director of Outreach and Strategic Partnerships to help shape and drive the strategic vision of our outreach programs. In this role, you'll collaborate with internal teams and external partners to develop and implement initiatives that engage patients, healthcare professionals, community organizations, and professional association volunteers. We're seeking a passionate, bilingual (English/Spanish) professional ready to make an impact. Think you’re the right fit? Learn more and apply today: https://bit.ly/4fUICGR

Everyone deserves to be as healthy as they can, no matter where they live, what language they speak or the color of their skin. But in kidney disease, race and ethnicity play a significant role. At the American Kidney Fund, we are working to change that — we believe in health equity. Hear about the importance of kidney health for all from AKF Ambassador Chris Bryant and learn more during #KidneyMonth: https://bit.ly/3tFRRZv

While people of all races and backgrounds get kidney disease, Black and Hispanic people are more likely to have diabetes and hypertension - the top two causes of kidney disease - and more likely to develop kidney failure. But kidney failure is often preventable. Talk with your patients, encourage them to get their kidneys checked and learn more about kidney health for all during #KidneyMonth: https://bit.ly/3tFRRZv

BREAKING: The FDA has approved Novartis US’s Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), a rare kidney disease, to reduce proteinuria. This is the first treatment approved for C3G. The approval comes after a study showed clinically meaningful proteinuria reduction in patients treated with Fabhalta. Learn more: https://bit.ly/4iPIpqy  #C3G #KidneyDisease

Chronic kidney disease (CKD) is a public health crisis—and its economic and societal impacts are huge. Our 2023 report, "Reimagining Kidney Care: From Crisis to Opportunity," revealed that fixing gaps in diagnosis, treatment access, and care delivery could save $9B in Medicare spending and $2.8B in commercial health plan costs—every year. Later this month, we’ll be unveiling a new report with The National Alliance of Healthcare Purchaser Coalitions, spotlighting CKD’s massive financial burden on employers—and the game-changing role they can play in turning the tide on CKD in the U.S. Dive deeper: https://bit.ly/3r1r7ku #KidneyHealth #WorkplaceWellness

We appreciate the opportunity to partner with Healthline Media this #KidneyMonth to provide educational resources to support those living with chronic kidney disease. Learn more below!

This #KidneyMonth, learn more about rare kidney diseases by hearing from patients themselves. AKF's Rare Kidney Disease Action Network (RKDAN) helps ensure that the voices of people fighting rare kidney diseases are heard and amplified. Do YOU work directly with rare kidney disease patients? Learn more about AKF's RKDAN and share with your patients: https://bit.ly/4hRE5H4 "Starting conversations with other people, whether they're patients or just a regular person, is so special because I get to share my story and then also raise awareness about IGA nephropathy. Because you never know who's dealing with a kidney disease that doesn't know about it." - Ariana B., AKF Rare Kidney Disease Action Network Member